skip to main content

    Updated Visitor Guidelines

 

MENU

 

Pancreatic Cancer

Rogel Cancer Center receives $50M to revolutionize pancreatic cancer care and research

Rogel Cancer Center receives $50M gift from Richard and Susan Rogel to aim to revolutionize how the world detects, treats, and ultimately cures pancreatic cancer.

Study offers reassurance for patients with some cancer-linked genes

Patients with cancer-linked variants in ATM, CHEK2 or PALB2 genes do not have a greater risk of dying from their disease, research finds

Drug targets identified for pancreatic cancer

Simultaneous targeting of PIKfyve and KRAS-MAPK eliminates tumors in preclinical human and mouse models

Lighting up cancer cells with biolasers

Researchers from the University of Michigan have developed a way of detecting circulating tumor cells in the bloodstream of pancreatic cancer and lung cancer patients. As tumors develop, they shed cells into the bloodstream. Although these circulating tumor cells are vastly outnumbered by millions of other blood cells, detecting them early can potentially improve treatment outcomes.

Tackling Pancreatic Cancer, Bench to Bedside

As part of the Next Generation series, meet Eileen Carpenter, M.D., Ph.D., a gastroenterologist who specializes in diseases of the pancreas. Running single-cell RNA sequencing and spatial transcriptomics on biorepository samples, her lab is working to identify biomarkers to guide therapeutic decisions in pancreatic cancer treatment.

Donor pancreas tissue helps define ‘new normal’ in pancreatic cancer research

A research partnership between Michigan Medicine and Gift of Life Michigan has revealed a new pathway to understanding the progression of pancreatic cancer.

Rogel Cancer Center receives $50M gift to revolutionize pancreatic cancer care, research

The gift will create the Rogel and Blondy Center for Pancreatic Cancer in honor of Max Rogel and Allen Blondy, Richard and Susan Rogel’s fathers, both of whom died from cancer. It will provide support for clinical care and translational research, playing to the strengths of the Rogel Cancer Center’s current robust team of 60 doctors and scientists from 10 departments already working in this area.

Pages